Breast Cancer Advice. Keep up to date with the latest information and treatment of breast cancer.
A Member of the Healthscout Network
 Printer Friendly  Send to a Friend

Protein Screen Predicts Breast Cancer Therapy Success

The test, called OncoPlan, is already available

FRIDAY, Sept. 15 (HealthDay News) -- A new test may help identify which breast cancer patients are most likely to benefit from chemotherapy.

The test, called OncoPlan, is already commercially available, and it has been shown to predict the aggressiveness of tumors and disease recurrence after surgery in breast, colon and stomach cancers. Now researchers believe it may help predict which breast cancer patients would benefit most from chemotherapy.

Related Stories
Black Women's Genes May Spur Deadlier Breast Cancer
Breast Cancer Drugs Not One-Size-Fits-All
Digital Mammography Boosts Chances of Spotting Malignancies
Related Videos
Attacking Advanced Breast Cancer
Keep Ovarian Cancer At Bay
Easing Radiation Side Effects
Related Slides
Breast Cancer
Breast Self-Exam

In a study presented at the first meeting on Molecular Diagnostics in Cancer Therapeutic Development, researchers looked at the two forms of protein measured by OncoPlan in 2,380 women with breast cancer, 717 of whom had undergone chemotherapy.

They found that the women who had low levels of one of the proteins and did not receive chemotherapy had very poor outcomes. The same women who did receive chemotherapy, however, had a twofold reduced risk of relapsing and dying from their disease.

The women who had high levels of the protein were much more likely to survive their disease, and appeared to derive no additional benefit from chemotherapy.

More research is needed to clarify the ability of OncoPlan in predicting outcomes of chemotherapy.

"But even at this point, the results are very exciting because, with further validation in clinical trials, OncoPlan, which is already being used to predict disease aggressiveness, will help to ensure that individual patients receive the most beneficial therapies," study author A. Raymond Frackelton Jr., an associate professor at Brown University and vice president of Research at Catalyst Oncology (the company marketing OncoPlan), said in a prepared statement.

More information

The National Cancer Institute has more about breast cancer ( ).

Krisha McCoy

SOURCE: American Association for Cancer Research, news release, Sept. 15, 2006

Copyright © 2006 ScoutNews LLC. All rights reserved.
Last updated 9/15/2006

Disclaimer: The information provided on this website is for educational purposes only and does not serve as a replacement for care provided by your own personal health care team. This website does not render or provide medical advice, and no individual should make any medical decisions or change their health behavior based on information provided here. All pertinent content provided on this website should be discussed with your personal physician to evaluate whether it has any relevance to or impact on your specific condition. Reliance on any information provided by this website is solely at your own risk.

Nov 14, 2006
New! For timely and trustworth health information, expert advice and much more, visit Breast Cancer Connection
Patient Guide
Health Videos
Health Encyclopedia
Health News Archive
Affiliate Information
HealthScout Network
Contact Us
Privacy Policy
Terms of Use

We subscribe to the HONcode principles of the Health On the Net Foundation
About The HealthScout Network Contact Us
Copyright 2001-2006 Choicemedia, Inc. All rights reserved.

Please visit our partner sites: